Loading stock data…
Opus Genetics, Inc. (IRD)
$4.06+0.06 (+1.50%)
Market ClosedLast close Jun 29
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Opus Genetics, Inc. in the Healthcare sector is trading at $4.06 with a market capitalization of $330M. Wall Street consensus targets $10.56 (18 analysts), implying a +160.0% move over the next 12 months. The stock is currently 30% below its 52-week high of $5.81, remaining 25.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +160.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.16M↓ | $3.87M↑ | $3.08M↑ | $2.88M↓ | $4.37M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.36M↓ | -$11.45M↓ | -$8.31M↑ | -$8.91M↑ | -$9.93M |
| Net Income | -$65.53M↓ | -$16.52M↑ | -$17.45M↓ | -$7.42M↑ | -$8.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$330.26M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
233.29%
Volume
Today's trading volume
816,129
Recent News
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target
While Opus Genetics, Inc. (NASDAQ:IRD) has gained 100.50% year-to-date, analysts continue to see 148.10% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Fresh coverage initiations and a series of positive data readouts have kept analyst attention firmly on this clinical-stage gene therapy company. On June 4, […]
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets’ 2026
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q1 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -20.57% and +1.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks
Opus Genetics Inc. (NASDAQ:IRD) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 6, Opus Genetics secured a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive funding and a $5 million equity investment. This capital infusion, combined with current resources, extends the company’s cash runway […]